Parker Waichman LLP

Raptiva Sales Suspension Recommended in Europe After Reports of Brain Infections

On the same day U.S. regulators warned that the psoriasis drug Raptiva had been linked to three fatal case of a rare brain infection, their counterparts in the European Union have recommended sales of the drug be suspended.  In a statement, advisers to the European Medicines Agency (EMEA)  said that in light of the deaths, […]

On the same day U.S. regulators warned that the psoriasis drug <"https://www.yourlawyer.com/topics/overview/Raptiva">Raptiva had been linked to three fatal case of a rare brain infection, their counterparts in the European Union have recommended sales of the drug be suspended.  In a statement, advisers to the European Medicines Agency (EMEA)  said that in light of the deaths, Raptiva’s benefits do not outweigh its risks.

Raptiva is an injectable drug that was approved by the  U.S. Food & Drug Administration (FDA) in 2003 to treat moderate to severe plaque psoriasis.  Raptiva works by blocking the activation of certain immune cells called T cells, and the migration of those cells into the skin. However, by suppressing the body’s natural defense system, it can also increase the risk of serious infections and malignancies in patients.

Yesterday, the FDA said that it had confirmed three fatal cases of the rare brain infection, progressive multifocal leukoencephalopathy (PML) in Raptiva patients.  The agency also said that it had learned of a suspected PML death in a fourth person treated with Raptiva.  The FDA said it was currently reviewing the latest information regarding Raptiva and PML, and is taking action to ensure that the risks of Raptiva do not outweigh its benefits.

Meanwhile, the  EMEAs Committee for Medicinal Products for Human Use said yesterday it had conducted a benefit/risk review of the drug, and concluded Raptiva’s benefits no longer outweigh its risks.   The European Commission will consider the advice. It usually follows EMEA recommendations.

Considering the cloud that Raptiva is now under, one analyst told Reuters that it is becoming. “increasingly likely” Raptiva would be pulled from the U.S. market.  In October 2008, the FDA had already required Genentech to place a Boxed Warning on the Raptiva label regarding the drugs’ risk of PML and other infectious diseases.

PML attacks the brain and central nervous system and is usually fatal.  It is caused by a polyomavirus, called the JC virus. The JC virus is often acquired during childhood. Most adults have been infected with the JC virus but do not develop PML. Symptoms include vision problems, loss of coordination, and memory loss. Patients who survive the disease are often permanently disabled.

Other drugs that suppress the immune system have also been linked to PML.  Last September, Genentech revised a warning on Rituxan to reflect the case of a rheumatoid arthritis patient who was treated with the medicine and died from PML.

Last summer, the FDA warned that the same brain disease had been associated with Tysabri, a drug for multiple sclerosis.  The FDA warning was prompted by reports of two European MS patients undergoing Tysabri monotherapy had developed PML. In the U.S., Tysabri was taken off the market in 2005 after three patients in clinical  trials developed PML.  But the drug was reapproved in 2006, although it was subject to restrictions.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Good morning, I felt very grateful with the result of the service you provided me thanks to Jorge Peniche and Jillian Cantinieri, without a doubt you would refer my friends, thank you
MERCEDES grullon
a year ago
5 Star Reviews 150
Positive: Professionalism , Quality , Responsiveness , Value I am so thankful for the service I received from PW LLP. I would also like to give a shoutout to Benita. She kept me informed in regard to my case.
Helen Washington
3 years ago
5 Star Reviews 150
I have been conversing via phone, text and email with Tina Morace and I am very happy with her service. Tina, is professional, courteous, attentive and respectful. Any time I have had a question or needed information, Tina has replied promptly and with all of the information I need.
Ray Nugent
a month ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038